文献速递胸部肿瘤

非小细胞肺癌肿瘤微环境图谱揭示放化疗后程序性死亡配体1阻断的耐药机制:多中心前瞻性生物标志物研究(WJOG11518L:SUBMARINE)

Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
PubMed 文献 · J Thorac Oncol · 2023-06-25

本研究为多中心前瞻性生物标志物研究,纳入135例接受PACIFIC方案(根治性同步放化疗后度伐利尤单抗巩固治疗)的不可切除III期非小细胞肺癌患者,通过免疫组化、转录组分析、基因组测序及循环免疫细胞流式分析探索耐药机制。结果显示肿瘤预存的有效适应性免疫与治疗获益相关,且癌细胞CD73表达为耐药机制;多变量分析显示低CD8+肿瘤浸润淋巴细胞密度和高CD73+癌细胞与度伐利尤单抗不良预后独立相关。全外显子测序提示癌细胞通过新抗原可塑性最终逃逸免疫压力。

要点

  • 低CD8+肿瘤浸润淋巴细胞密度与度伐利尤单抗不良预后独立相关(HR=4.05)。
  • 高CD73+癌细胞与度伐利尤单抗不良预后独立相关(HR=4.79)。
  • 全外显子测序提示癌细胞通过新抗原可塑性逃逸免疫压力。

核心结论

  • 研究强调III期非小细胞肺癌中功能性适应性免疫的重要性,并提示CD73是有前景的治疗靶点,为开发新的治疗策略提供依据。

研究设计与样本

  • 多中心前瞻性生物标志物研究(WJOG11518L:SUBMARINE),纳入135例接受PACIFIC方案的不可切除III期非小细胞肺癌患者。
  • 对治疗前肿瘤组织进行免疫组化、转录组分析和基因组测序,并对循环免疫细胞进行流式细胞分析。
  • 基于上述生物标志物比较无进展生存期。

主要发现

  • 无论基因组特征如何,肿瘤预存的有效适应性免疫对治疗获益具有重要性。
  • 癌细胞CD73表达被确定为对PACIFIC方案的耐药机制。
  • 多变量分析显示,低CD8+肿瘤浸润淋巴细胞密度与度伐利尤单抗不良预后独立相关(HR=4.05,95%CI:1.17-14.04)。
  • 高CD73+癌细胞与度伐利尤单抗不良预后独立相关(HR=4.79,95%CI:1.12-20.58)。
  • 配对肿瘤样本的全外显子测序提示癌细胞通过新抗原可塑性最终逃逸免疫压力。

关键数值与推荐

  • 低CD8+肿瘤浸润淋巴细胞密度:HR=4.05(95%CI:1.17-14.04)。
  • 高CD73+癌细胞:HR=4.79(95%CI:1.12-20.58)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The PACIFIC regimen of consolidation therapy with the programmed cell death-ligand 1 inhibitor durvalumab after definitive concurrent chemoradiation therapy has become a standard of care for individuals with unresectable stage III NSCLC. Nevertheless, approximately half of the treated patients experience disease progression within 1 year, with the mechanisms of treatment resistance being poorly understood. We here performed a nationwide prospective biomarker study to explore the resistance mechanisms (WJOG11518L:SUBMARINE). METHODS: A total of 135 patients with unresectable stage III NSCLC who received the PACIFIC regimen were included for comprehensive profiling of the tumor microenvironment by immunohistochemistry, transcriptome analysis, and genomic sequencing of pretreatment tumor tissue and flow cytometric analysis of circulating immune cells. Progression-free survival was compared on the basis of these biomarkers. RESULTS: The importance of preexisting effective adaptive immunity in tumors was revealed for treatment benefit regardless of genomic features. We also identified CD73 expression by cancer cells as a mechanism of resistance to the PACIFIC regimen. Multivariable analysis of immunohistochemistry data with key clinical factors as covariables indicated that low CD8+ tumor-infiltrating lymphocyte density and the high CD73+ cancer cells were independently associated with poor durvalumab outcome (hazard ratios = 4.05 [95% confidence interval: 1.17-14.04] for CD8+ tumor-infiltrating lymphocytes; 4.79 [95% confidence interval: 1.12-20.58] for CD73). In addition, whole-exome sequencing of paired tumor samples suggested that cancer cells eventually escaped immune pressure as a result of neoantigen plasticity. CONCLUSIONS: Our study emphasizes the importance of functional adaptive immunity in stage III NSCLC and implicates CD73 as a promising treatment target, thus providing insight forming a basis for development of a new treatment approach in NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Haratani K, Nakamura A, Mamesaya N, et al. Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE). J Thorac Oncol. 2023. PMID: 37364849. doi:10.1016/j.jtho.2023.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。